Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with ...
Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...
Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results